Clinical TrialJul 2, 2026, 06:08 AM
Molecular Partners Doses First Patients in Phase 1/2a DLL3 Radio-DARPin Trial
AI Summary
Molecular Partners AG and Orano Med announced that the first patients have been dosed in the US multicenter Phase 1/2a study of their drug candidate MP0712. MP0712 is a DLL3-targeting 212Pb-labelled Radio-DARPin, designed to treat small cell lung cancer and other neuroendocrine tumors. Initial data from the trial is expected in the coming months of 2026, with comprehensive efficacy data anticipated in 2027.
Key Highlights
- First patients dosed in US multicenter Phase 1/2a study of MP0712.
- MP0712 is a DLL3-targeting 212Pb-labelled Radio-DARPin.
- Developed in strategic partnership between Molecular Partners and Orano Med.
- Initial data from the study anticipated within the coming months (2026).
- Comprehensive efficacy data expected in 2027.
- Five centers are currently open and actively recruiting in the US.
Price Impact
More from MOLN